Home - Recludix Pharma About Who we are Mission & commitment Leadership Investors & partners Contact Science SH2-targeted therapies Platform Pipeline Overview REX-8756 
(STAT6 inhibitor) BTK inhibitor Patients Our commitment Clinical trials Role of STAT6 News & Events Highlights Press releases Events & presentations Careers Culture & values Benefits Job openings Rewriting futures Developing new medicines for people living with inflammatory diseases Driven to transform the lives of people with inflammatory diseases By tackling the toughest protein targets with selective inhibitors, we’re creating the next generation of oral precision medicines – innovative therapies designed to redefine treatment, offering people safer, more effective options to manage their conditions. Explore our pipeline Unlocking the previously undruggable SH2 domain SH2 domains are essential for regulating the localization and activity of proteins and play a central role in mediating cellular signals that trigger specific responses. Dysregulation of the cellular pathways that utilize SH2-domain containing proteins drives certain disorders, including inflammatory diseases. Once considered undruggable, our platform integrates new chemical approaches and technologies to enable the successful development of therapies to inhibit SH2 domains, resulting in the inhibition of dysregulated cellular pathways. Discover our platform Latest news Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at the European Association of Allergy and Clinical Immunology (EAACI) and Revolutionizing Atopic Dermatitis (RAD) CongressesJune 12, 2026 Recludix Pharma to Present at RBC Capital Markets Global Healthcare ConferenceMay 18, 2026 Recludix Pharma Announces Preclinical Data Demonstrating Efficacy Comparable to Monoclonal Antibodies Targeting IL-4/IL-13 Signaling Pathways and Differentiated Safety Profile of Oral STAT6 Inhibitor REX-8756 (also known as SAR448755) in a Model of Atopic DermatitisMay 15, 2026 Business development/ partnerships: [email protected] General inquiries: [email protected] San Diego headquarters 3010 Science Park Road, Suite 200 San Diego, CA 92121 858.258.5445 Cambridge office 222 Third Street, Suite 1320 Cambridge, MA 02142 858.258.5445 in Privacy Policy | Terms of Use © 2026 Recludix All Rights Reserved × Previous Next × MENU About Who we are Mission & commitment Leadership Investors & partners Contact Science SH2-targeted therapies Platform Pipeline Overview REX-8756 
(STAT6 inhibitor) BTK inhibitor Patients Our commitment Clinical trials Role of STAT6 News & Events Highlights Press releases Events & presentations Careers Culture & values Benefits Job openings